Issues
-
Cover Image
Cover Image
IL34 is expressed in primary lung adenocarcinoma tissues and correlates with poor prognosis in cancer patients. IL34, a cytokine that acts as a second ligand for CSF1R, was found to be induced and controlled by chronic activation of NF-κB in chemoresistant lung cancer cells. In vitro and in vivo experiments unveiled a dual role for IL34 in cancer chemoresistance. IL34 was found to enhance local immunosuppression by tumor-associated macrophages and also provides cancer cells with a critical survival signal to overcome chemotherapeutic conditions. For details, see article by Baghdadi and colleagues on page 6030. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Breaking Advances
Cancer Research 75th Anniversary Commentary
Reviews
Priority Report
Clinical Studies
Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging
Water Concentration Analysis by Raman Spectroscopy to Determine the Location of the Tumor Border in Oral Cancer Surgery
Integrated Systems and Technologies
Improving the Performance of Somatic Mutation Identification by Recovering Circulating Tumor DNA Mutations
Microenvironment and Immunology
Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming
Chemotherapy-Induced IL34 Enhances Immunosuppression by Tumor-Associated Macrophages and Mediates Survival of Chemoresistant Lung Cancer Cells
Molecular and Cellular Pathobiology
Prevention and Epidemiology
Impact of Serum Antibodies to HPV Serotypes 6, 11, 16, and 18 to Risks of Subsequent Genital HPV Infections in Men: The HIM Study
Body Mass Index, Waist Circumference, Diabetes, and Risk of Liver Cancer for U.S. Adults
Therapeutics, Targets, and Chemical Biology
The PARP Inhibitor AZD2461 Provides Insights into the Role of PARP3 Inhibition for Both Synthetic Lethality and Tolerability with Chemotherapy in Preclinical Models
Deep Sequencing Reveals a Novel miR-22 Regulatory Network with Therapeutic Potential in Rhabdomyosarcoma
Tumor and Stem Cell Biology
WWOX and p53 Dysregulation Synergize to Drive the Development of Osteosarcoma
CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma
Corrections
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.